Dr. Yu received his undergraduate degree in chemistry from Fudan University in 2001. He received his Ph.D. in Chemistry from the University of California, Berkeley in 2006 under the direction of Julie Leary, where he developed mass spectrometric approaches for the study of protein-ligand interactions. As a graduate student, he also developed a series of proteomic technologies for the study of tyrosine sulfation, a protein post-translational modification that is implicated in regulating protein-protein interactions in the extracellular space.
In 2007, Dr. Yu joined the laboratories of Steven Gygi and John Blenis in the Department of Cell Biology at Harvard Medical School for his post-doctoral training (in both quantitative proteomics and signal transduction). There he developed quantitative mass spectrometric strategies for the study of protein phosphorylation. He deployed these powerful technologies to characterize the PI3K/Akt/mTORC1 pathway, and identified their downstream signaling modules that control a variety of cellular anabolic processes.
In 2012, Dr. Yu began his independent research career as an Assistant Professor in the Department of Biochemistry at UT Southwestern Medical Center. He was promoted to Associate Professor with tenure in 2017. Throughout his career, Dr. Yu has been the recipient of numerous awards for his research, including the Tuberous Sclerosis Alliance Postdoctoral Fellowship, a CPRIT Scholar in Cancer Research award, a Virginia Murchison Linthicum Scholar in Medical Research award, a Research Scholar award from the American Cancer Society, a UT System Rising STARs Award and most recently, an R35 MIRA award from NIGMS. He has served on many NIH and DoD advisory panels, including as a current member of the NIH Enabling Bioanalytical and Imaging Technologies (EBIT) Study Section.
The long-term goals of the Yu lab are to develop cutting-edge, mass spectrometry-based proteomic technologies, and applying these powerful tools to systematically discover novel protein modifications and the related "dark matter" within in the human proteome. These data-driven strategies are then combined with classical biochemistry approaches to chacterize aberrant protein modification patterns, decipher the mechanisms of their deregulation, establish the functional consequences of these molecular events, facilitate the development of relevant therapeutic strategies, and finally, identify proteomic signatures that may serve as diagnostic, prognostic or predictive biomarkers for the relevant diseases (e.g., cancer, diabetes and neurodegenerative disease).
- Fudan University (2001), Chemistry
- Graduate School
- Univ of California-Berkeley (2006), Chemistry
- Chemical Biology
- Mass Spectrometry
- Post-translational Modifications (e.g. Phosphorylation and ADP-ribosylation)
- Quantitative Proteomics and Chemoproteomics
- Signal Transduction and Metabolism
- Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.
- Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO Proc. Natl. Acad. Sci. U.S.A. 2011 Nov 108 47 E1204-13
- Sensitive multiplexed analysis of kinase activities and activity-based kinase identification.
- Kubota K, Anjum R, Yu Y, Kunz RC, Andersen JN, Kraus M, Keilhack H, Nagashima K, Krauss S, Paweletz C, Hendrickson RC, Feldman AS, Wu CL, Rush J, Villén J, Gygi SP Nat. Biotechnol. 2009 Oct 27 10 933-40
- A site-specific, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectrometry.
- Yu Y, Anjum R, Kubota K, Rush J, Villen J, Gygi SP Proc. Natl. Acad. Sci. U.S.A. 2009 Jul 106 28 11606-11
- CCR2 chemokines bind selectively to acetylated heparan sulfate octasaccharides.
- Schenauer MR, Yu Y, Sweeney MD, Leary JA J. Biol. Chem. 2007 Aug 282 35 25182-8
- Heterodimerization of CCR2 chemokines and regulation by glycosaminoglycan binding.
- Crown SE, Yu Y, Sweeney MD, Leary JA, Handel TM J. Biol. Chem. 2006 Sep 281 35 25438-46
- Effects of sulfate position on heparin octasaccharide binding to CCL2 examined by tandem mass spectrometry.
- Sweeney MD, Yu Y, Leary JA J. Am. Soc. Mass Spectrom. 2006 Aug 17 8 1114-9
- Potential inhibitors of chemokine function: analysis of noncovalent complexes of CC chemokine and small polyanionic molecules by ESI FT-ICR mass spectrometry.
- Yu Y, Sweeney MD, Saad OM, Leary JA J. Am. Soc. Mass Spectrom. 2006 Apr 17 4 524-35
- Chemokine-glycosaminoglycan binding: specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry.
- Yu Y, Sweeney MD, Saad OM, Crown SE, Hsu AR, Handel TM, Leary JA J. Biol. Chem. 2005 Sep 280 37 32200-8
- Mechanism and kinetics of metalloenzyme phosphomannose isomerase: measurement of dissociation constants and effect of zinc binding using ESI-FTICR mass spectrometry.
- Gao H, Yu Y, Leary JA Anal. Chem. 2005 Sep 77 17 5596-603
- Mass spectrometric analysis of the human 40S ribosomal subunit: native and HCV IRES-bound complexes.
- Yu Y, Ji H, Doudna JA, Leary JA Protein Sci. 2005 Jun 14 6 1438-46
Honors & Awards
- R35 MIRA award
- Special issue of Future of Biochemistry
- Developmental Research Program Award
NCI Lung Cancer SPORE (Specialized Programs of Research Excellence) (2017)
- Young Investigator Award
Chinese American Diabetes Association (2017)
- ACS Research Scholar
American Cancer Society (2015)
- CPRIT Scholar in Cancer Research
Cancer Prevention Research Institute of Texas (2011)
- University of Texas STARS award
University of Texas System (2011)
- Virginia Murchison Linthicum Scholar in Medical Research
UT Southwestern Medical Center (2011)
- Tuberous Sclerosis Alliance Postdoctoral Fellowship
Tuberous Sclerosis Alliance (2008)
- Chun-Tsung Scholar
Chun-Tsung Endowment (1999)
- American Association for Cancer Research (2013)
- American Society for Mass Spectrometry (2001)